Testosterone vs Boldenone: What to Choose and for Whom
The editorial team regularly receives the query "which is better — testosterone or boldenone." The honest answer depends on who is asking and why. For a patient with hypogonadism, the choice exists only within registered testosterone products, whereas for a healthy person seeking an athletic effect, the correct question sounds different: what risks are they prepared to take on.
How to frame the question of choice correctly
In medicine, the choice of a drug begins with a diagnosis. The physician first confirms the condition requiring treatment, assesses contraindications, and only then selects the substance, form, and regimen. Any "what to choose" comparison without a diagnosis is a comparison of risks, not of benefits.
Testosterone and boldenone lie in different planes. The first is a registered medicinal product with clinical guidelines. The second is a veterinary substance that in most countries is not registered for humans and has no official indications.
For this reason, in a conversation about choice the editorial team distinguishes three situations: medical (there is a confirmed hormone deficiency), athletic (a healthy person wants to improve results), and informational (a person wants to understand the issue in order to make an informed decision or persuade loved ones to refrain).
For each of these situations the answer is different. In the medical one — the physician chooses among testosterone products. In the athletic one — none of the options is safe, and the most important thing is to understand exactly which risks are associated with each. In the informational one — it is useful to know the facts we set out below.
Who is testosterone indicated for
According to the Endocrine Society guideline (2018), testosterone therapy is considered in men with clinical symptoms of androgen deficiency and consistently low testosterone confirmed by at least two morning fasting tests.
Typical symptoms include reduced libido, erectile dysfunction, fewer morning erections, loss of muscle mass, reduced bone mineral density, and anemia of unclear origin. The diagnosis is made only by combining the clinical presentation and laboratory data, not by a single indicator.
It is important to establish the cause of the deficiency: primary hypogonadism (damage to the testes) or secondary (damage to the pituitary or hypothalamus). The workup and even the choice of treatment depend on this: for men planning to have children, testosterone replacement therapy is usually unsuitable, as it suppresses spermatogenesis.
The guideline also defines contraindications under which therapy is not prescribed or is postponed pending further examination.
- a partner planning pregnancy in the near future;
- prostate or breast cancer;
- a palpable prostate nodule or elevated PSA without a urological examination;
- hematocrit above 48–50%;
- untreated severe obstructive sleep apnea;
- uncontrolled heart failure, recent myocardial infarction, or stroke.
Thus, even in a medical context testosterone "suits" not everyone. The decision is made by the physician after examination, and therapy entails regular monitoring of hematocrit, PSA, and hormone level.
Are there indications for boldenone
Boldenone undecylenate was historically used in veterinary medicine as an anabolic agent for animals. For humans it has no approved indications in most jurisdictions, and it is absent from modern clinical guidelines.
This means that a situation in which a physician would choose boldenone instead of testosterone does not exist in evidence-based medicine. For treating hypogonadism there is testosterone, for anemia in chronic kidney disease there are other agents, for sarcopenia — primarily training and nutrition.
In informal sources boldenone is presented as an agent "for quality mass" and "with fewer side effects." However, these claims are not supported by controlled human studies. Most of the described "advantages" are extrapolations of animal data and users' personal impressions.
Additionally, quality must be taken into account: a person using boldenone almost always obtains a product of illegal manufacture with unknown composition and sterility. This is a separate and often underestimated risk, unrelated to the pharmacology of the molecule itself.
| Situation | Testosterone | Boldenone |
|---|---|---|
| Confirmed hypogonadism in a man | May be prescribed by a physician | Not used |
| A man planning to have children | Replacement therapy is usually unsuitable | Contraindicated by mechanism (suppression of spermatogenesis) |
| A woman without medical indications | Risk of virilization | Risk of virilization |
| An athlete undergoing doping control | Prohibited (WADA S1) | Prohibited (WADA S1) |
| Product quality control | Pharmaceutical, by prescription | Predominantly illegal market |
Groups for whom the risks are especially high
Adolescents and young people who have not finished growing are the most vulnerable group. Androgens accelerate the closure of bone growth plates, and suppression of the hormonal axis at this age can have lasting consequences for reproductive health.
Women have a high risk of virilization from any androgen. Deepening of the voice, clitoral enlargement, and male-pattern hair growth may be irreversible. Despite the common myth, boldenone is no exception and has no "female" safety profile.
People with cardiovascular risk factors — arterial hypertension, dyslipidemia, a family history of early myocardial infarction — are especially sensitive to the effects of androgens on lipids, blood clotting, and the myocardium. A review by Baggish and colleagues (2017) describes, in anabolic steroid users, reduced pumping function of the heart and accelerated atherosclerosis of the coronary arteries.
People predisposed to depression, anxiety, or impulsivity also belong to the risk group: androgens can affect mood, and after discontinuation a state of low mood and libido, associated with a deficiency of one's own testosterone, often develops.
Sport, doping control, and legal consequences
Both substances belong to section S1 "Anabolic Agents" of the WADA Prohibited List and are banned both in and out of competition. For an athlete undergoing testing there is no choice between them: any positive result means a violation of anti-doping rules.
Exogenous testosterone is detected by the testosterone-to-epitestosterone ratio, the steroid profile in the athlete's biological passport, and isotope-ratio mass spectrometry, which distinguishes the synthetic origin of the hormone from the endogenous one.
Boldenone is detected by specific metabolites. It is known that small amounts of boldenone can sometimes form endogenously or through microbial processes in the sample, so to confirm exogenous origin laboratories also apply isotope analysis.
Beyond sport, the legal aspect should be considered: the circulation of prescription and veterinary steroids without appropriate authorizations is regulated in many countries by legislation on medicines or controlled substances. Liability depends on the jurisdiction, but these risks themselves are real.
Editorial conclusions
The question "what to choose" makes sense only in a medical context, and there the answer is unambiguous: for confirmed hypogonadism the physician considers testosterone products, whereas boldenone is not used in clinical practice.
For healthy people, neither substance is a "safe choice." The shared risks — suppression of the hormonal axis, changes in blood and lipids, strain on the heart — are compounded, for boldenone, by insufficient study and the low quality of illegal products.
The most vulnerable groups — adolescents, women, people with cardiovascular and psychiatric risk factors — must refrain from non-medical use of androgens.
We also recommend reading our materials on the symptoms and diagnosis of hypogonadism, on the recovery of the hormonal system after androgen use, and on which tests are worth taking to assess cardiovascular risk.
References
- Bhasin S, Brito JP, Cunningham GR, et al. Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2018;103(5):1715–1744.
- Pope HG Jr, Wood RI, Rogol A, et al. Adverse health consequences of performance-enhancing drugs: an Endocrine Society scientific statement. Endocr Rev. 2014;35(3):341–375.
- Baggish AL, Weiner RB, Kanayama G, et al. Cardiovascular toxicity of illicit anabolic-androgenic steroid use. Circulation. 2017;135(21):1991–2002.
- Rahnema CD, Lipshultz LI, Crosnoe LE, et al. Anabolic steroid-induced hypogonadism: diagnosis and treatment. Fertil Steril. 2014;101(5):1271–1279.
- Kicman AT. Pharmacology of anabolic steroids. Br J Pharmacol. 2008;154(3):502–521.
- World Anti-Doping Agency. The Prohibited List. International Standard. Montreal: WADA; 2025.
Andriy Melnyk
A strength-sports coach and author of programs for beginner and intermediate levels. Writes about training planning.
